![conference banner](/images/conference-banner.jpeg)
摘要
背景:虽然化疗主要用于癌症治疗,但它可能无效,并可能产生严重的副作用,导致化疗耐药。有必要发现新的药物,既能增强抗肿瘤活性,又能抵消化疗的严重副作用。已知P物质(SP)/神经激肽-1受体(NK-1R)相互作用系统在癌症的发病机制中起关键作用。对NK-1R拮抗剂(如aprepitant)的研究表明,NK-1R是治疗癌症的潜在靶点。Aprepitant(阿瑞匹坦)与主要化疗药物联合使用已显示出增加抗肿瘤活性和减少副作用的潜力。 目的:由于恶性肿瘤癌症细胞过度表达NK-1R,这种联合治疗是治疗各种癌症的一种有希望的方法。由于该药物显示出广泛的抗肿瘤药物的潜力,因此有必要将这种NK-1R拮抗剂重新用作抗肿瘤药物。本综述还将概述与阿普列汀/放疗联合治疗相关的研究。本综述的目的是提供与癌症化疗/放疗和NK-1R拮抗剂相关的联合研究的最新进展。 结论:这种联合策略一旦得到证实,可能为化疗和放疗开辟一个新的时代,具有更大的抗肿瘤活性和更少的副作用。这种治疗策略可能转化为癌症患者更高的治愈率、更好的生活质量和更少的后遗症。
关键词: 阿瑞匹坦(Aprepitant), NK-1拮抗剂1, 化疗、放疗、P物质、联合治疗、抗肿瘤、癌症。
[http://dx.doi.org/10.1016/j.clon.2004.06.007] [PMID: 15630849]
[http://dx.doi.org/10.3390/cancers12092682] [PMID: 32962202]
[http://dx.doi.org/10.1155/2015/495704] [PMID: 26421291]
[http://dx.doi.org/10.4103/0019-509X.31164] [PMID: 17401221]
[http://dx.doi.org/10.3390/cancers13061349] [PMID: 33802704]
[http://dx.doi.org/10.3390/cancers13112703] [PMID: 34070805]
[http://dx.doi.org/10.1002/ijc.28433] [PMID: 23934616]
[http://dx.doi.org/10.1016/j.biopha.2018.09.013] [PMID: 30223097]
[http://dx.doi.org/10.1007/s10549-013-2599-6] [PMID: 23807418]
[http://dx.doi.org/10.1073/pnas.1908998116] [PMID: 31488714]
[http://dx.doi.org/10.1016/j.bbrc.2019.05.092] [PMID: 31109645]
[http://dx.doi.org/10.1016/j.peptides.2013.07.024] [PMID: 23933301]
[http://dx.doi.org/10.1016/0026-2862(90)90024-L] [PMID: 1701206]
[http://dx.doi.org/10.1073/pnas.190276697] [PMID: 10995467]
[http://dx.doi.org/10.1073/pnas.0610664104] [PMID: 17264209]
[http://dx.doi.org/10.3892/ijo.2013.2164] [PMID: 24190675]
[http://dx.doi.org/10.1016/j.jhep.2013.12.024] [PMID: 24412605]
[http://dx.doi.org/10.23937/2378-3419/3/6/1071]
[http://dx.doi.org/10.1074/jbc.M312363200] [PMID: 14769794]
[http://dx.doi.org/10.1038/s41598-017-09639-7] [PMID: 28842601]
[http://dx.doi.org/10.1007/s11523-013-0300-y] [PMID: 24233638]
[http://dx.doi.org/10.18632/oncotarget.1932] [PMID: 24811362]
[http://dx.doi.org/10.3389/fonc.2020.00584] [PMID: 32391269]
[http://dx.doi.org/10.18632/oncotarget.20557] [PMID: 29207651]
[http://dx.doi.org/10.1038/nature13119] [PMID: 24670641]
[http://dx.doi.org/10.1038/cr.2014.61] [PMID: 24810303]
[http://dx.doi.org/10.1093/carcin/bgs167] [PMID: 22581827]
[http://dx.doi.org/10.1517/13543780903563364] [PMID: 20074015]
[http://dx.doi.org/10.1007/s00432-014-1872-3] [PMID: 25391371]
[http://dx.doi.org/10.1007/s11033-020-05532-1] [PMID: 32436041]
[http://dx.doi.org/10.1007/s11033-020-05330-9] [PMID: 32072401]
[http://dx.doi.org/10.1186/s12974-018-1098-4] [PMID: 29486768]
[http://dx.doi.org/10.1016/j.bbrc.2011.08.075] [PMID: 21875579]
[http://dx.doi.org/10.4049/jimmunol.181.3.1665] [PMID: 18641302]
[http://dx.doi.org/10.1007/s10637-009-9218-8] [PMID: 19148578]
[http://dx.doi.org/10.1038/labinvest.2010.92] [PMID: 20458280]
[http://dx.doi.org/10.1517/14740338.2013.804059] [PMID: 23706125]
[http://dx.doi.org/10.1097/QAD.0000000000000638] [PMID: 25915168]
[http://dx.doi.org/10.1016/j.lungcan.2014.03.017] [PMID: 24746177]
[http://dx.doi.org/10.1007/s11060-015-1996-6] [PMID: 26603162]
[http://dx.doi.org/10.1371/journal.pone.0010968] [PMID: 20532044]
[http://dx.doi.org/10.1016/j.ejphar.2020.173168] [PMID: 32423870]
[http://dx.doi.org/10.1172/jci.insight.95893] [PMID: 28978797]
[http://dx.doi.org/10.1007/s11010-019-03677-7] [PMID: 31853800]
[http://dx.doi.org/10.1093/annonc/mdp194] [PMID: 19541792]
[http://dx.doi.org/10.1007/s10637-018-0607-8] [PMID: 29721755]
[http://dx.doi.org/10.1016/j.jpainsymman.2021.02.007] [PMID: 33587995]
[http://dx.doi.org/10.2340/00015555-3148] [PMID: 30734049]
[http://dx.doi.org/10.1016/j.biocel.2018.08.010] [PMID: 30145367]
[http://dx.doi.org/10.3390/cancers3011351] [PMID: 24212665]
[http://dx.doi.org/10.3390/cancers13205178] [PMID: 34680400]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.902221] [PMID: 20100968]
[http://dx.doi.org/10.1152/ajpheart.00099.2014] [PMID: 25217655]
[http://dx.doi.org/10.1002/pbc.20492] [PMID: 16333817]
[http://dx.doi.org/10.1186/1471-2407-10-337] [PMID: 20587042]
[http://dx.doi.org/10.1007/978-3-030-43032-0_15] [PMID: 32483740]
[http://dx.doi.org/10.1155/2016/1959270] [PMID: 26981525]
[http://dx.doi.org/10.3390/cancers13071732] [PMID: 33917491]
[http://dx.doi.org/10.18632/oncotarget.13440] [PMID: 27888795]
[http://dx.doi.org/10.1096/fasebj.23.1_supplement.756.13]
[http://dx.doi.org/10.1056/NEJMra1406184] [PMID: 26376137]
[http://dx.doi.org/10.2147/DDDT.S244648] [PMID: 32606608]
[http://dx.doi.org/10.1016/j.lrr.2017.03.001] [PMID: 28462082]
[http://dx.doi.org/10.1097/CAD.0000000000000591] [PMID: 29389803]
[http://dx.doi.org/10.1002/advs.202101936] [PMID: 34605226]
[http://dx.doi.org/10.1097/FJC.0000000000000163] [PMID: 25343568]
[http://dx.doi.org/10.1159/000493256] [PMID: 30792647]
[http://dx.doi.org/10.1056/NEJMc1013027] [PMID: 21288111]
[http://dx.doi.org/10.1136/bmjopen-2019-030114] [PMID: 32034016]
[http://dx.doi.org/10.3892/mco.2019.1857] [PMID: 31289677]
[http://dx.doi.org/10.3390/cancers13071732] [PMID: 33917491]
[http://dx.doi.org/10.3390/pharmaceutics11090443] [PMID: 31480582]
[http://dx.doi.org/10.3390/molecules25163756] [PMID: 32824729]
[http://dx.doi.org/10.1007/978-3-540-36719-2]
[http://dx.doi.org/10.3390/molecules23102542] [PMID: 30301182]
![Wayfinder Image](/images/wayfinder.jpg)